Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001564590-22-016913
Filing Date
2022-05-02
Accepted
2022-05-02 06:10:52
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A trvi-defa14a_20220429.htm DEFA14A 16456
2 GRAPHIC gu3pfb4x0ywp000001.jpg GRAPHIC 229694
3 GRAPHIC gu3pfb4x0ywp000002.jpg GRAPHIC 82660
  Complete submission text file 0001564590-22-016913.txt   447508
Mailing Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Filer) CIK: 0001563880 (see all company filings)

EIN.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-38886 | Film No.: 22879249
SIC: 2834 Pharmaceutical Preparations